Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Rating Upgraded by Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Friday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 0.9%

Shares of NASDAQ BDRX opened at $2.15 on Friday. Biodexa Pharmaceuticals has a twelve month low of $2.03 and a twelve month high of $92.00. The stock has a 50 day moving average of $3.69 and a two-hundred day moving average of $5.82.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.